Genentech Reports the Acquisition of Regor's CDK Inhibitors Portfolio Targeting Breast Cancer
Shots:
- Regor Pharmaceuticals and Genentech have signed a definitive purchase agreement under which the former will acquire a portfolio of next-generation CDK inhibitors targeting breast cancer
- As per the agreement, Genentech will pay $850M upfront in cash and additional milestones on attaining predetermined development, regulatory and commercial success. The transaction is anticipated to close during Q4’24, pending customary closing conditions
- Genentech will handle global clinical development, manufacturing & commercialization, while Regor will complete the two ongoing P-I studies and continue advancing its other assets focused on oncology, metabolic diseases & autoimmunity
Ref: PR Newswire | Image: Regor
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
